Press Releases

Press Releases

November 7, 2019
Aptose to Present at BIO-Europe Conference
November 6, 2019
Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting
November 5, 2019
Aptose Reports Results for the Third Quarter Ended September 30, 2019
October 22, 2019
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019
October 10, 2019
Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)
September 16, 2019
Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies
August 6, 2019
Aptose Reports Results for the Second Quarter Ended June 30, 2019
July 30, 2019
Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference
July 23, 2019
Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019
July 16, 2019
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
June 14, 2019
Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
June 4, 2019
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
June 3, 2019
Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer
June 3, 2019
Aptose Announces Closing of Public Offering of Common Shares
May 31, 2019
Aptose to Present at the Jefferies 2019 Healthcare Conference
May 30, 2019
Aptose Announces Pricing of Public Offering of Common Shares
May 29, 2019
Aptose Announces Proposed Public Offering of Common Shares
May 24, 2019
Aptose Biosciences Establishes New At-The-Market Facility
May 16, 2019
Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association
May 13, 2019
Aptose to Present at May Investor Conferences
May 10, 2019
Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC
May 7, 2019
Aptose Reports Results for the First Quarter Ended March 31, 2019
April 24, 2019
Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2019
April 23, 2019
Aptose To Release First Quarter Ended March 31, 2019 Financial Results and Hold Conference Call on May 7, 2019
April 2, 2019
Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
April 1, 2019
Aptose Presents New Preclinical Data on CG-806 and APTO-253 at the 2019 AACR Annual Meeting
March 25, 2019
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
March 12, 2019
Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2018
March 7, 2019
Aptose to Participate in Upcoming Investor Conferences in March 2019
March 4, 2019
Aptose Biosciences and CrystalGenomics Announce Issuance of Australian Patent for CG-806
February 28, 2019
Aptose to Present New CG-806 and APTO-253 Data at the 2019 AACR Annual Meeting
February 26, 2019
Aptose To Release Fourth Quarter and Year End December 31, 2018 Financial Results and Hold Conference Call on March 12, 2019
February 25, 2019
Aptose Biosciences Submits IND Application for CG-806
February 19, 2019
Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference
January 2, 2019
Aptose Biosciences to Present at Biotech Showcase™ 2019 Conference